Archives

New mouse models may shed light on the puzzling aspects of SARS-CoV-2 infection May 27, 2021 LA JOLLA—The La Jolla Institute for Immunology (LJI) is partnering with Synbal, Inc., a preclinical [...]

There is an urgent need for new animal models of SARS CoV-2 infection to improve research and drug development. This brief commentary examines the deficits of current models and proposes several [...]

BIOCENTURY | EMERGING COMPANY PROFILE BY MARK ZIPKIN, STAFF WRITER Synbal is tapping new genetic approaches to develop both rodents with humanized metabolisms and cell therapies for lysosomal [...]

Synbal is proud to announce that several members of our Scientific Advisory Board, Drs. K. Cooper, V. Gantz and E. Bier have published another landmark paper in the journal Nature.  The paper [...]

SAN DIEGO, Calif., November 26, 2018—Synbal, Inc., a biotechnology company developing non-viral, cell-based gene therapy candidates for rare diseases, cancer, autoimmune and degenerative [...]

The unifying theme of Dr. Kim Cooper’s research program centers on identifying the developmental and genetic mechanisms that reshaped the vertebrate limb during evolution. Soon after Dr. Cooper [...]

Sibylle’s international professional career spans over 20 years in global Pharma, emerging Biotech and biologic contract manufacturing with a successful track record in corporate business [...]